CASE REPORT article

Front. Med.

Sec. Dermatology

Successful Management of DPP-4 Inhibitor-Induced Bullous Pemphigoid with Stapokibart Injection in an Elderly Diabetic Patient: A Case Report

  • 1. Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China

  • 2. Deyang Hospital Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, Deyang China., Deyang, China

The final, formatted version of the article will be published soon.

Abstract

Dipeptidyl peptidase-4 (DPP-4) inhibitors, such as linagliptin, have been implicated in inducing bullous pemphigoid (BP) in elderly diabetic patients. Stapokibart is a humanized monoclonal antibody targeting interleukin-4 receptor subunit alpha (IL-4Rα), primarily used for atopic dermatitis, with no prior reports of its application in BP. This article describes a case of DPP-4 inhibitor-induced bullous pemphigoid treated with Stapokibart. Following Stapokibart therapy, the patient exhibited complete resolution of skin lesions, significant improvement in quality of life, and no adverse reactions. This case suggests that Stapokibart may be an effective treatment for bullous pemphigoid induced by DPP-4 inhibitors.

Summary

Keywords

Bullous pemphigoid, diabetes, dipeptidyl peptidase-4 inhibitors, Linagliptin, Stapokibart

Received

27 November 2025

Accepted

18 February 2026

Copyright

© 2026 Yu, Tian and Meng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Shue Tian; Fanlin Meng

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Share article

Article metrics